# US 2021/0171531 A1 · Masp-2 inhibitors and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171531 A1
- Document ID: US20210171531A1
- Status: Published application
- Kind: A1
- Application number: 17/112,896
- Filed: 2020-12-04
- Published: 2021-06-10
- Earliest claimed: 2019-12-04
- Assignees: Omeros Corporation
- Applicants: Omeros Corporation
- Inventors: Michael CICIRELLI; Neil S. CUTSHALL; Jennifer Lynn GAGE; Sara Rebecca GOLDSTEIN; Santosh Kumar KESHIPEDDY; Do Yeon KWON; Robert Huerta LEMUS; Thomas L. LITTLE; Markus METZ; Jeremiah H. NGUYEN; Peter Kurt NOLLERT VON SPECHT; Loren Michael PRICE; Jennifer TSOUNG; Sudheer Babu VADDELA
- Web page: https://patentgrep.com/patent/US20210171531A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07F 9/59: Hydrogenated pyridine rings
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

## Claims

### Claim 1

A compound having the following Structure (I):
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:
at each occurrence, independently represents a double or single bond;
R1 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl;
R2 is hydrogen, alkyl, alkoxy, haloalkyl, hydroxyalkyl, haloalkoxy, or cycloalkyl;
R3 is hydrogen, alkyl, haloalkyl, or cycloalkyl, or R2 and R3, together with the carbon and nitrogen to which they are attached, respectively, form an optionally substituted 4-7 membered heterocyclyl;
R4 is a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
R5 is hydrogen, alkyl, haloalkyl, cycloalkyl, phosphonalkyl, (CH2)mC(═O)OR6, C(═O)R6, C(═O)OR6, (CH2)mNR6S(O)2R7, or C(═O)NR6R7;
R6 and R7 are, at each occurrence, independently hydrogen, alkyl, haloalkyl, cycloalkyl, or arylalkyl;
L1 is a direct bond, —CR8aR8b, —S(O)t—, NR8c, or —O—;
R8a and R8b are each independently hydrogen, alkyl, or R8a and R8b, together with the carbon to which they are attached form an optionally substituted 3-6 membered cycloalkyl;
R8c is hydrogen, alkyl, haloalkyl, (C═O)alkyl, (C═O)Oalkyl, (C═O)cycloalkyl, (C═O)Ocycloalkyl, (C═O)aryl, (C═O)Oaryl, (C═O)heteroaryl, (C═O)Oheteroaryl, (C═O)heterocyclyl, (C═O)O heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted arylalkyl, a substituted or unsubstituted heteroarylalkyl, a substituted or unsubstituted cycloalkylalkyl, or a substituted or unsubstituted heterocyclylalkyl;
n is 1 or 2;
m is 1, 2, 3, 4, 5, or 6; and
t is 0, 1, or 2,
provided that the compound of Structure (I) does not have a structure in Table A.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is a substituted or unsubstituted phenyl.

### Claim at position 4

5-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein R1 has one of the following structures:

### Claim at position 6

12-16. (canceled)

### Claim 17 (depends on 1)

The compound of claim 1, wherein R1 is a substituted or unsubstituted heteroaryl.

### Claim at position 8

18-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1, wherein R1 has one of the following structures:

### Claim at position 10

29-30. (canceled)

### Claim 31 (depends on 1)

The compound of claim 1, wherein R1 is a substituted or unsubstituted cycloalkyl.

### Claim at position 12

32-36. (canceled)

### Claim 37 (depends on 1)

The compound of claim 1, wherein R1 is a substituted or unsubstituted heterocyclyl.

### Claim at position 14

38-42. (canceled)

### Claim 43 (depends on 1)

The compound of claim 1, wherein R2 is hydrogen, C1-C6 alkyl, or R2 and R3, together with the carbon and nitrogen to which they are attached, respectively, form an optionally substituted 4-7 membered heterocyclyl.

### Claim at position 16

44-61. (canceled)

### Claim 62 (depends on 1)

The compound of claim 1, wherein R4 is a substituted or unsubstituted aryl.

### Claim 63

(canceled)

### Claim 64 (depends on 1)

The compound of claim 1, wherein R4 is a substituted or unsubstituted phenyl.

### Claim at position 20

65-67. (canceled)

### Claim 68 (depends on 1)

The compound of claim 1, wherein R4 has one of the following structures:

### Claim 69 (depends on 1)

The compound of claim 1, wherein R4 is a substituted or unsubstituted heteroaryl.

### Claim at position 23

70-73. (canceled)

### Claim 74 (depends on 1)

The compound of claim 1, wherein R4 has one of the following structures:

### Claim 75

(canceled)

### Claim 76 (depends on 1)

The compound of claim 1, wherein R5 is hydrogen, alkyl, phosphonalkyl, (CH2)mNR6S(O)2R7, or (CH2)mC(═O)OR6.

### Claim at position 27

77-80. (canceled)

### Claim 81 (depends on 76)

The compound of claim 76, wherein R5 has one of the following structures:

### Claim at position 29

82-87. (canceled)

### Claim 88 (depends on 1)

The compound of claim 1, wherein L1 is a direct bond, —O—, or —CH2—.

### Claim at position 31

89-90. (canceled)

### Claim 91 (depends on 1)

The compound of claim 1, wherein L1 is —CR8aR8b and R8a and R8b together with the carbon to which they are attached form an optionally substituted 3, 4, or 5 membered cycloalkyl.

### Claim at position 33

92-94. (canceled)

### Claim 95

A compound having one of the structures in Table 1 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

### Claim 96 (depends on 1)

A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 97 (depends on 1)

A method for treating a MASP-2-associated disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1.

### Claim at position 37

98-132. (canceled)

### Claim 133 (depends on 1)

The compound of claim 1, wherein R1 has one of the following structures:
